MISX:GEMA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

International Medical Center of Biomaterials Processing and Cryostorage

Executive Summary

International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company operates as a licensed bank for personal storage of cord blood stem cells in Russia and the CIS countries.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has International Medical Center of Biomaterials Processing and Cryostorage's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GEMA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.4%

GEMA

3.9%

RU Healthcare

2.8%

RU Market


1 Year Return

n/a

GEMA

0.9%

RU Healthcare

0.9%

RU Market

Return vs Industry: Insufficient data to determine how GEMA performed against the Russian Healthcare industry.

Return vs Market: Insufficient data to determine how GEMA performed against the Russian Market.


Shareholder returns

GEMAIndustryMarket
7 Day-1.4%3.9%2.8%
30 Day-14.9%8.8%4.4%
90 Day-17.9%-7.4%-13.6%
1 Yearn/a1.6%0.9%7.7%0.9%
3 Yearn/a-17.9%-21.0%53.1%28.7%
5 Yearn/a-1.2%-6.7%115.8%68.5%

Price Volatility Vs. Market

How volatile is International Medical Center of Biomaterials Processing and Cryostorage's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is International Medical Center of Biomaterials Processing and Cryostorage undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GEMA (RUB630) is trading below our estimate of fair value (RUB1413.3)

Significantly Below Fair Value: GEMA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GEMA is good value based on its PE Ratio (8.2x) compared to the Healthcare industry average (21.5x).

PE vs Market: GEMA is poor value based on its PE Ratio (8.2x) compared to the Russian market (8.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GEMA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GEMA is overvalued based on its PB Ratio (4.8x) compared to the XE Healthcare industry average (1.8x).


Next Steps

Future Growth

How is International Medical Center of Biomaterials Processing and Cryostorage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as International Medical Center of Biomaterials Processing and Cryostorage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether International Medical Center of Biomaterials Processing and Cryostorage is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • International Medical Center of Biomaterials Processing and Cryostorage competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has International Medical Center of Biomaterials Processing and Cryostorage performed over the past 5 years?

32.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GEMA has high quality earnings.

Growing Profit Margin: GEMA's current net profit margins (48.9%) are lower than last year (59.4%).


Past Earnings Growth Analysis

Earnings Trend: GEMA's earnings have grown significantly by 32.9% per year over the past 5 years.

Accelerating Growth: GEMA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GEMA had negative earnings growth (-17.6%) over the past year, making it difficult to compare to the Healthcare industry average (-2%).


Return on Equity

High ROE: GEMA's Return on Equity (59.1%) is considered outstanding.


Next Steps

Financial Health

How is International Medical Center of Biomaterials Processing and Cryostorage's financial position?


Financial Position Analysis

Short Term Liabilities: GEMA's short term assets (RUB227.7M) exceed its short term liabilities (RUB115.8M).

Long Term Liabilities: GEMA's short term assets (RUB227.7M) exceed its long term liabilities (RUB219.2M).


Debt to Equity History and Analysis

Debt Level: GEMA's debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GEMA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GEMA's debt is well covered by operating cash flow (569.9%).

Interest Coverage: GEMA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is International Medical Center of Biomaterials Processing and Cryostorage's current dividend yield, its reliability and sustainability?


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GEMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GEMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GEMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GEMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GEMA's dividend in 3 years as they are not forecast to pay a notable one for the Russian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

International Medical Center of Biomaterials Processing and Cryostorage has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: GEMA only recently listed within the past 12 months.


Top Shareholders

Company Information

International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company
  • Ticker: GEMA
  • Exchange: MISX
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: ₽940.585m
  • Shares outstanding: 1.49m
  • Website: https://www.gemabank.ru

Location

  • International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company
  • P.1, Room 24, House 3, Building 1
  • Floor 1
  • Moscow
  • Moskovskaya obl.
  • 119333
  • Russia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GEMAMISX (Micex - Rts)YesOrdinary SharesRURUBJul 2019

Biography

International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company operates as a licensed bank for personal storage of cord blood stem cells in Russia and the CIS countries. The company is based in Moscow, Russia. International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company is a subsidiary of Human Stem Cells Institute PJSC. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/26 01:05
End of Day Share Price2020/05/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.